Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonafarnib and Docetaxel in Advanced Cancer
NCT00539968Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Primary completion
- Dec 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of lonafarnib in prostate cancer (PCa), breast cancer, ovarian cancer and 2 more, sponsored by Merck & Co. Primary endpoints: Incidence of adverse events and dose-limiting toxicities and Rate of prostate-specific antigen (PSA) responses. Started Jun 2007; status: terminated.
02
Drugs
lonafarnib
03
Conditions
prostate cancer (PCa)breast cancerovarian cancerlung cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT00539968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00539968.